SCA
PCRX icon

Stuart Chaussee & Associates’s Pacira BioSciences PCRX Stock Holding History

Stuart Chaussee & Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-125
Closed -$4K – 76
2016
Q3 		$4K Hold
125
– – ﹤0.01% 71
2016
Q2 		$4K Hold
125
– – ﹤0.01% 71
2016
Q1 		$8K Hold
125
– – 0.01% 69
2015
Q4 		$10K Buy
+125
New +$7.08K 0.01% 62

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Stuart Chaussee & Associates's PCRX Position: Q4 2016 in Review

Stuart Chaussee & Associates sold out of Pacira BioSciences (PCRX) in Q4 2016, closing a stake of 125 shares — an estimated $4K sold.

Stuart Chaussee & Associates first reported a position in PCRX in Q4 2015 and held it in 4 quarters. The position peaked at $10K in Q4 2015. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • Stuart Chaussee & Associates reported no remaining Pacira BioSciences position as of Q4 2016 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 125 Pacira BioSciences shares in Q4 2016, an estimated $4K.
  • Stuart Chaussee & Associates first reported a position in Pacira BioSciences in Q4 2015 and held it in 4 quarters.
  • Stuart Chaussee & Associates's Pacira BioSciences position peaked at $10K in Q4 2015.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on Stuart Chaussee & Associates's 13F filing for Q4 2016, filed 18 Jan 2017.